Robert A Blake

US Patent:

40691705, Jan 17, 1978

Filed:

Dec 13, 1976

Appl. No.:

5/750027

Inventors:

Robert J. Blake - Oakland CA
Guy W. Roy - Richmond CA

Assignee:

Stauffer Chemical Company - Westport CT

International Classification:

B01J 2706

US Classification:

252441

Abstract:

Catalyst compositions comprising mixtures of salts of copper, potassium, didymium, lanthanum and magnesium are useful in the fluidized bed oxychlorination of aliphatic hydrocarbons. The catalyst composition loading is disposed on a suitable support media, preferably an alumina and does not cake or cause defluidization of the bed under start-up, operating, or shut-down conditions.

US Patent:

42848334, Aug 18, 1981

Filed:

Dec 19, 1977

Appl. No.:

5/862242

Inventors:

Robert J. Blake - Oakland CA
Guy W. Roy - Richmond CA

Assignee:

Stauffer Chemical Company - Westport CT

International Classification:

C07C 17152

US Classification:

570224

Abstract:

The active life of an oxychlorination copper-containing catalyst is extended by the removal of sulfur-containing compounds from the gases fed to the catalyst reaction zone. A copper-containing oxychlorination catalyst which has been deactivated by the deposition of sulfur compounds thereon is reactivated in situ by operating the catalyst bed in an oxygen-free atmosphere for a sufficient period of time. The reactivation of the catalyst is completed when the conversions of hydrocarbon and chlorinating agent to chlorinated products indicate a high level of catalyst activity, as determined by an analysis of the gaseous effluent leaving the catalyst bed.

US Patent:

61143715, Sep 5, 2000

Filed:

Nov 12, 1998

Appl. No.:

9/190970

Inventors:

Peng Cho Tang - Moraga CA
Li Sun - Foster City CA
Gerald McMahon - Kenwood CA
Robert A. Blake - Foster City CA

Assignee:

Sugen, Inc. - So. San Francisco CA

International Classification:

A01N 4338
A61K 31535
C07D41304
C07D40104
C07D40504

US Classification:

514414

Abstract:

The present invention relates to novel 3-(cyclohexano-heteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.

US Patent:

20230067037, Mar 2, 2023

Filed:

Apr 23, 2021

Appl. No.:

17/239086

Inventors:

- South San Francisco CA, US
Thomas PILLOW - South San Francisco CA, US
Robert Anthony BLAKE - South San Francisco CA, US
Ingrid WERTZ - South San Francisco CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 47/68
A61K 31/427
A61K 31/5517
A61K 31/661

Abstract:

The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.